NICE says no to AZ’s Lynparza for prostate cancer
pharmaphorum
MARCH 8, 2021
The cost-effectiveness agency is assessing use of Lynparza (olaparib) in patients with tumours that carry BRCA1 or BRCA2 mutations who have previously been treated with the hormone therapies abiraterone and enzalutamide but have relapsed.
Let's personalize your content